Evidence map›Paper›PMID 41608415›Full record

ReviewFrontiers in medicine2025

The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications.

Song Wen, Chenglin Xu, Yue Yuan, Lijiao Chen, Yishu Ren, Zhimin Xu, Jianlan Jin, Jiyu Li, Ligang Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Song Wen *Pudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Chenglin Xu *Pudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Yue Yuan *Pudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Lijiao ChenPudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Yishu RenPudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Zhimin XuPudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Jianlan JinPudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Jiyu LiPudong Medical Center, Department of Surgery, Shanghai Pudong Hospital, Fudan University, Shanghai, China.
Ligang ZhouPudong Medical Center, Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR), a major cause of vision loss in working-age adults, manifests as a microvascular complication of diabetes, with early-stage non-proliferative diabetic retinopathy (NPDR) requiring timely intervention. This review explores the molecular mechanisms underlying early DR, including microvascular damage, inflammation, oxidative stress, and advanced glycation end products, with distinct profiles in type 1 and type 2 diabetes. Novel antidiabetic medications, such as GLP-1 receptor agonists, SGLT-2 inhibitors, and dual GIP/GLP-1 agonists, target these pathways, may have potential to reduce NPDR progression expected in clinical trials. Advanced diagnostics, including ultra-widefield fundus photography, OCT, OCTA, and AI-based algorithms, achieve over 95% accuracy in detecting NPDR and predicting systemic risks like cardiovascular disease. This article highlights the therapeutic implications of novel antidiabetic drugs, advocating for integrated diagnostic and treatment strategies to mitigate DR's global burden and preserve vision.

Indexed as

artificial intelligence (AI) diagnosticsdiabetic retinopathyincretin-based therapyoptical coherence tomography (OCT)SGLT-2 inhibitorstype 1 diabetestype 2 diabetes

Identifiers

PMID41608415
PMCPMC12835220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.